Chimeric antigen receptor (CAR)-T-cell therapy for solid tumors is limited due to
heterogeneous target antigen expression and outgrowth of tumors lacking the antigen …

Targeting solid tumor antigens with chimeric antigen receptor (CAR) T cell therapy requires
tumor specificity and tolerance toward variability in antigen expression levels. Given the …

Purpose: Chimeric antigen receptor (CAR) transduced T cells represent a promising
immune therapy that has been shown to successfully treat cancers in mice and humans …

Most solid tumors are comprised of multiple clones that express orthogonal antigens,
suggesting that novel strategies must be developed in order to adapt chimeric antigen …

Glioblastoma multiforme (GBM) is the most common malignant brain cancer that invades
normal brain tissue and impedes surgical eradication, resulting in early local recurrence and …

Chimeric antigen receptor–T cell (CAR-T) therapy has been effective in the treatment of
hematologic malignancies, but it has shown limited efficacy against solid tumors. Here we …

Chimeric antigen receptors (CARs) are synthetic molecules designed to redirect T cells to
specific antigens. CAR-modified T cells can mediate long-term durable remissions in B cell …

Adoptive therapy with chimeric antigen receptor (CAR) T cells shows great promise
clinically. However, there are important aspects of CAR-T-cell biology that have not been …

Background Glioblastoma (GBM) is the most common primary malignant brain cancer, and
is currently incurable. Chimeric antigen receptor (CAR) T cells have shown promise in GBM …

Chimeric antigen receptors (CAR)-transduced T cells hold great promise in the treatment of
malignant disease. Here, we demonstrate that intracerebral injection with a human …